Financial results for the period ended September 30, 2026
As filed · Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
EarningsNotablemateriality 70 out of 100
What happened
FactFinancial results for the period ended September 30, 2026.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Order Book
WithdrawnEarlierQ1 FY27
Revenue from operations grew 22.8% to INR 2,580 crore, reflecting strong execution across both domestic and international businesses.
NowQ1 FY27
The order book across the different countries should also go up in line with the supplies.
Change
FactGuidance withdrawn
Implication
CapitSignal interpretationThe earlier statement provided a specific revenue growth figure, while the current statement does not provide a specific target or figure for the order book, indicating a withdrawal of guidance.confidence 90%
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- I believe that going forward, whether it is Q2, Q3, Q4, you will see the northward movements as far as the Ind (management committed by Q4 FY27)
- I would like to reiterate my confidence in Emcure to deliver low to mid-teen revenue growth in FY27. (management committed by FY27)
Evidence
- Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%